Oral delivery of peptide and protein drugs faces immense challenge partially due to the gastrointestinal (GI) environment. In spite of considerable efforts by industrial and academic laboratories, no major breakthrough in the effective oral delivery of polypeptides and proteins has been accomplished. Upon oral administration, gastrointestinal epithelium acts as a physical and biochemical barrier for absorption of proteins resulting in low bioavailability (typically less than 1-2%). An ideal oral drug delivery system should be capable of (a) maintaining the integrity of protein molecules until it reaches the site of absorption, (b) releasing the drug at the target absorption site, where the delivery system appends to that site by virtue of specific interaction, and (c) retaining inside the gastrointestinal tract irrespective of its transitory constraints. Various technologies have been explored to overcome the problems associated with the oral delivery of macromolecules such as insulin, gonadotropin-releasing hormones, calcitonin, human growth factor, vaccines, enkephalins, and interferons, all of which met with limited success. This review article intends to summarize the physiological barriers to oral delivery of peptides and proteins and novel pharmaceutical approaches to circumvent these barriers and enhance oral bioavailability of these macromolecules.
Oral delivery of peptide andpan class="Chemical">protein drugs faces immense challenge partially due to the gastrointestinal (GI) environment. In spite of considerable efforts by industrial and academic laboratories, no major breakthrough in the effective oral delivery of polypeptides and proteins has been accomplished. Upon oral administration, gastrointestinal epithelium acts as a physical and biochemical barrier for absorption of proteins resulting in low bioavailability (typically less than 1-2%). An ideal oral drug delivery system should be capable of (a) maintaining the integrity of protein molecules until it reaches the site of absorption, (b) releasing the drug at the target absorption site, where the delivery system appends to that site by virtue of specific interaction, and (c) retaining inside the gastrointestinal tract irrespective of its transitory constraints. Various technologies have been explored to overcome the problems associated with the oral delivery of macromolecules such as insulin, gonadotropin-releasing hormones, calcitonin, human growth factor, vaccines, enkephalins, and interferons, all of which met with limited success. This review article intends to summarize the physiological barriers to oral delivery of peptides and proteins and novel pharmaceutical approaches to circumvent these barriers and enhance oral bioavailability of these macromolecules.
Authors: Gioconda Millotti; Glen Perera; Claudia Vigl; Karin Pickl; Frank Michael Sinner; Andreas Bernkop-Schnürch Journal: Drug Deliv Date: 2010-11-02 Impact factor: 6.419
Authors: Trizel du Toit; Maides M Malan; Hendrik J R Lemmer; Chrisna Gouws; Marique E Aucamp; Wilma J Breytenbach; Josias H Hamman Journal: Eur J Drug Metab Pharmacokinet Date: 2016-10 Impact factor: 2.441
Authors: Leonie H E Leithold; Nan Jiang; Julia Post; Tamar Ziehm; Elena Schartmann; Janine Kutzsche; N Jon Shah; Jörg Breitkreutz; Karl-Josef Langen; Antje Willuweit; Dieter Willbold Journal: Pharm Res Date: 2015-09-17 Impact factor: 4.200
Authors: Michael Clinton Koetting; Joseph Frank Guido; Malvika Gupta; Annie Zhang; Nicholas A Peppas Journal: J Control Release Date: 2015-12-02 Impact factor: 9.776